Ascendis Pharma (ASND) Reports Q3 Loss of EUR1.04

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR1.04), versus (EUR0.72) reported last year.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• H.C. Wainwright Starts Ascendis Pharma (ASND) at Buy
• Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
• Ulta Beauty (ULTA) Tops Q2 EPS by 38c, Offers Outlook